Tudor Investment Corp ET AL Lowers Position in BioCryst Pharmaceuticals, Inc. $BCRX

Tudor Investment Corp ET AL cut its holdings in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 45.2% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 98,175 shares of the biotechnology company’s stock after selling 80,909 shares during the quarter. Tudor Investment Corp ET AL’s holdings in BioCryst Pharmaceuticals were worth $745,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also modified their holdings of the company. Focus Partners Wealth purchased a new position in shares of BioCryst Pharmaceuticals during the 3rd quarter worth $77,000. Farther Finance Advisors LLC raised its holdings in shares of BioCryst Pharmaceuticals by 326.8% in the 3rd quarter. Farther Finance Advisors LLC now owns 10,590 shares of the biotechnology company’s stock valued at $80,000 after buying an additional 8,109 shares during the period. Mercer Global Advisors Inc. ADV purchased a new stake in shares of BioCryst Pharmaceuticals in the 3rd quarter valued at $81,000. Vestmark Advisory Solutions Inc. purchased a new stake in shares of BioCryst Pharmaceuticals in the 3rd quarter valued at $81,000. Finally, Elevation Point Wealth Partners LLC purchased a new stake in shares of BioCryst Pharmaceuticals in the 3rd quarter valued at $81,000. 85.88% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the company. Evercore assumed coverage on BioCryst Pharmaceuticals in a report on Wednesday, February 18th. They issued an “outperform” rating and a $17.00 price objective on the stock. Royal Bank Of Canada cut their price objective on BioCryst Pharmaceuticals from $14.00 to $13.00 and set an “outperform” rating on the stock in a report on Friday, January 30th. Finally, Weiss Ratings upgraded BioCryst Pharmaceuticals from a “sell (d-)” rating to a “hold (c)” rating in a report on Wednesday, March 4th. Ten research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat, BioCryst Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average target price of $19.64.

Insider Transactions at BioCryst Pharmaceuticals

In other BioCryst Pharmaceuticals news, insider Alane P. Barnes sold 150,000 shares of the stock in a transaction dated Monday, March 16th. The stock was sold at an average price of $9.15, for a total value of $1,372,500.00. Following the sale, the insider owned 400,703 shares of the company’s stock, valued at $3,666,432.45. This trade represents a 27.24% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 5.10% of the stock is owned by corporate insiders.

BioCryst Pharmaceuticals Price Performance

BCRX stock opened at $9.67 on Wednesday. The firm has a market capitalization of $2.43 billion, a P/E ratio of 8.06 and a beta of 0.70. The business’s 50-day moving average is $8.43 and its two-hundred day moving average is $7.62. BioCryst Pharmaceuticals, Inc. has a 1 year low of $6.00 and a 1 year high of $11.31.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its quarterly earnings results on Thursday, February 26th. The biotechnology company reported $1.12 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.07 by $1.05. The company had revenue of $163.28 million for the quarter, compared to analyst estimates of $151.32 million. BioCryst Pharmaceuticals had a negative return on equity of 84.33% and a net margin of 30.16%.BioCryst Pharmaceuticals’s revenue for the quarter was up 209.1% compared to the same quarter last year. During the same quarter last year, the company earned ($0.13) EPS. On average, analysts expect that BioCryst Pharmaceuticals, Inc. will post -0.36 EPS for the current year.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.